Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A potent and brain permeable amyloid ligand has been identified as a lead compound capable of I-123/125-labelling for single photon emission computed tomography (SPECT) imaging. In this study, we report the synthesis and I-125-radiolabelling of Compound 6 and its in vitro and in vivo properties. Compound 6 [2-(3′-iodo-4′-aminophenyl)-6-hydroxybenzothiazole] bound to synthetic Aβ(1–40) fibrils in a saturable manner, exhibiting an affinity (Ki) of 11±1.1 nM in a competitive binding assay using a tritiated thioflavin T analog ([3H]BTA-1) as radioligand. [125I]6 binding to synthetic Aβ(1–40) fibrils fit a single-site model. [125I]6 exhibited several-fold higher binding to homogenates of frontal cortex from post-mortem Alzheimer’s disease brain relative to age-matched control brain homogenates. No difference in binding was observed in cerebellum. The ratio of radioactivity concentration between frontal cortex and cerebellum was 6-fold higher in AD brain homogenates than the age-matched control. [125I]6 also readily penetrated the blood-brain barrier in normal control mice with an average radioactivity concentration of 6.43 ± 0.62%ID/g detected in the whole brain at 2 min post i.v. injection. At 30 min, the radioactivity concentration decreased to 0.40 ± 0.05%ID/g, indicating good clearance in the absence of amyloid deposits in the brain.
- De Strooper B. and Konig G. (1999) Alzheimer’s disease: a firm base for drug development. Nature 402(6761), 471–472. CrossRef
- Frenkel D., Katz O., and Solomon B. (2000) Immunization against Alzheimer’s β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. USA 97(21), 11455–11459. CrossRef
- Friedland R. P., Majocha R. E., Reno J. M., Lyle L. R., and Marotta C. A. (1994) Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer’s disease. Mol. Neurobiol. 9(1–3), 107–113.
- Hardy J. A. and Higgins G. A. (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256(5054), 184–185. CrossRef
- Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., et al. (2000) Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer’s disease. Nature 408(6815), 979–982. CrossRef
- Klunk W. E., Debnath M. L., and Pettegrew J. W. (1994) Development of small molecule probes for the β-amyloid protein of Alzheimer’s disease.” Neurobiol. Aging 15(6), 691–698. CrossRef
- Klunk W. E., Wang Y. M., Hung G. F., Debnah M. L., Holt D. P., and Mathis C. A. (2001) Uncharged thioflavin-T derivatives bind to amyloid-β protein with high affinity and readily enter the brain. Life Sci. 69, 1471–1484. CrossRef
- Mathis C. A., Bacskai B. J., Kajdasz S. T., et al. (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging in brain. Bioorg. Med. Comm. 12, 295–298. CrossRef
- Mochizuki A., Peterson J. W., Mufson E. J., and Trapp B. D. (1996) Amyloid load and neural elements in Alzheimer’s disease and nondemented individuals with high amyloid plaque density. Exp. Neurol. 142(1), 89–102. CrossRef
- Naslund J., Haroutunian V., Mohs R., Davis K. L., Davies P., Greengard P., and Buxbaum J. D. (2000) Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283(12), 1571–1577. CrossRef
- Octave J. N. (1995). The amyloid peptide and its precursor in Alzheimer’s disease. Rev. Neurosci. 6(4), 287–316.
- Schenk D. B., Seubert P., Lieberburg I., and Wallace J. (2000) β-Peptide immunization: a possible new treatment for Alzheimer disease. Arch. Neurol. 57(7), 934–936. CrossRef
- Selkoe D. J. (2000) Imaging Alzheimer’s amyloid. Nature Biotechnol. 18(8), 823–4. CrossRef
- Selkoe D. J. (2000) Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein. Ann. NY Acad. Sci. 924, 17–25. CrossRef
- Skovronsky D. M., Zhang B., Kung M. P., Kung H. F., Trojanowski J. Q., and Lee V. M. (2000) In vivo detection of amyloid plaques in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 97(13), 7609–14. CrossRef
- Styren S. D., Hamilton R. L., Styren G. C., and Klunk W. E. (2000) X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer’s disease pathology. J. Histochem. Cytochem. 48(9), 1223–1232.
- Varadarajan S., Yatin S., Aksenova M., and Butterfield D. A. (2000) Review: Alzheimer’s amyloid-β peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130(2–3), 184–208. CrossRef
- Wang Y. M., Klunk W. E., Huang G.-F., Debnah M. L., Holt D. P., and Mathis C. A. (2001) Synthesis and evaluation of a radioiodinated benzothiazole derivative as a radioligand for in vivo quantitation of β-amyloid deposits in aging and Alzheimer’s disease. J. Labelled Compounds Radiopharmaceut. 44(Suppl.1), S239-S241.
- Wengenack T. M., Curran G. L., and Poduslo J. F. (2000) Targeting Alzheimer amyloid plaques in vivo. Nature Biotechnol. 18(8), 868–872. CrossRef
- Wolfe M. S., Citron M., Diehl T. S., Xia W., Donkor I. O., and Selkoe D. J. (1998). A substrate-based difluoro ketone selectively inhibits Alzheimer’s γ-secretase activity. J. Med. Chem. 41(1), 6–9. CrossRef
- Zhuang Z. P., Kung M. P., Hou C., Skovronsky D. M., Gur T. L., Plossl K., et al. (2001). Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J. Med. Chem. 44(12), 1905–1914. CrossRef
- Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease
Journal of Molecular Neuroscience
Volume 19, Issue 1-2 , pp 11-16
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Alzheimer’s disease
- Industry Sectors
- Author Affiliations
- 1. PET Facility, Department of Radiology, Western Psychiatric Institute and Clinic, School of Medicine, University of Pittsburgh, 15213, Pittsburgh, PA
- 2. Department of Psychiatry, Western Psychiatric Institute and Clinic, School of Medicine, University of Pittsburgh, 15213, Pittsburgh, PA